1. 2001;4;317-321Metastatic Prostate Cancer to the Spine and a PSA of 5666: A Case Report
   A Case Report
   Evan S. Siegelman, MD, Rajeev K. Patel, MD, Curtis W. Slipman, MD, Atul L. Bhat, MD, Michael Cirigliano, MD, Zacharia Isaac, MD, and David Lenrow, MD.

Prostate cancer is the most commonly diagnosed cancer and the second most common cause of cancer death among American men. To our knowledge, the highest reported prostate specific antigen (PSA) level on initial presentation is 3280 ng/mL (1). In this case report, we discuss a 46-year-old African-American man with back pain of 1-month’s duration. A magnetic resonance imaging study of the lumbar spine revealed numerous osseous metastatic lesions, and the PSA level was found to be 5666 ng/mL. He was treated with oral narcotics and a Duragesic patch to achieve analgesia and bicalutamide (Casodex®) and leuprolide acetate (Lupron®) therapy for androgen blockade. Later in his course, he required chemotherapy due to hormone-refractory prostate cancer. The patient has done well as shown at his latest follow-up at 48 months. The objective of this report is to discuss the first patient with metastatic prostate cancer to the spine with PSA level greater than 3,500 ng/mL.

Keywords: Spine metastasis, prostate cancer, prostatic specific antigen, magnetic resonance imaging